The aim of our work was to develop and validate a hydrophilic interaction liquid chromatography-electrospray ionization-tandem mass spectrometry (HILIC-ESI-MS/MS) methods for the quantification of tobramycin (TMC) and lincomycin (LMC)in plasma, microdialysis fluid and urine. Methods: Protein precipitation was used to extract TMC and LMC from plasma, while microdialysis fluid and urine sample were diluted prior to instrumental analysis. Mobile phase A consisted of 2 mM ammonium acetate in 10% acetonitrile with 0.2% formic acid (v/v) and mobile phase B consisted of 2 mM ammonium acetate in 90% acetonitrile with 0.2% formic acid (v/v). Gradient separation (80%-10% of mobile phase B) for TMC was done using a SeQuant zic-HILIC analytical guard column. While separation of LMC was performed using gradient elution (100%-40% of mobile phase B) on a SeQuant zic-HILIC analytical column equipped with a SeQuant zic-HILIC guard column. Vancomycin (VCM) was used as an internal standard. A quadratic calibration was obtained over the concentration range for plasma of 0.1-20 mg/L for TMC and 0.05-20 mg/L for LMC, for microdialysis fluid of 0.1-20 mg/L for both TMC and LMC, and 1-100 mg/L for urine for both TMC and LMC. Results: For TMS and LMC, validation testing for matrix effects, precision and accuracy, specificity and stability were all within acceptance criteria of ±15%. Conclusions: The methods described here meet validation acceptance criteria and were suitable for application in a pilot pharmacokinetic research study performed in a sheep model.
Introduction
Tobramycin (TMC) is an aminoglycoside antibiotic used for treating serious infections caused by aerobic Gramnegative bacteria, including Pseudomonas aeruginosa [1] . TMC is administered via intra-venous, -muscular route or inhalation and eliminated mostly unchanged in urine [2] . Lincomycin (LMC) is a lincosamide antibiotic that is indicated for treatment of mixed anaerobic and aerobic infections (such as bone and articular infections and skin and soft tissue infections) [3] . LMC is administered via oral, intra -venous or -muscular route and undergoes hepatic metabolism that leads to elimination of LMC in the bile and approximately 20% in urine [4] .
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a common technique for determination of drug concentrations in biological matrices. Prior methods have been reported for the determination of TMC in drainage tissue fluid of osteomyelitis patient samples [5] , serum [6] , bone [7] , tear fluid [8] , plasma and microdialysis fluid [9] . Methods for the determination of LMC in urine by capillary electrophoresis (CE) and electrochemiluminescence (ECL) detection [10] , in tissues by gas chromatography with nitrogen-phosphorus detection [11, 12] , in kidney [13] , muscle (of cattle, swine and chicken) and bovine milk [14] , chickens feathers and edible tissues [15] using HPLC-MS/MS, and in swine manure using laser diode thermal desorption-atmospheric pressure chemical ionization-MS/MS [16] have been reported. TMC and LMC are highly hydrophilic in nature [17] . There are limitations (such as poor resolution and ion suppression with electrospray ionization [ESI]) associated with use of reverse-phase chromatography in the separation of polar compounds [18] . Hydrophilic interaction chromatography (HILIC) allows improved retention and resolution of highly polar compounds from interferences in complex matrices [19] . Only two HILIC-MS/MS methods have been reported for the determination of TMC in serum [20] and plasma samples [21] . For quantification of LMC, there is only one analytical method reported using HILIC [22] , and no analytical method has been published for a pharmacokinetic study of LMC in plasma, urine and microdialysis fluid using HILIC.
Sensitive and reliable analytical methodology is needed to analyze the TMC and LMC in biological matrices. Microdialysis is a technique for continuous sampling of unbound drug concentration in tissue [23] . To the best of our knowledge, this paper is the first to describe the application of HILIC-MS to measure TCM in microdialysate and urine samples, and LMC in plasma, microdialysate and urine samples. The validated methods were successfully applied to a pilot pharmacokinetic research study performed on an ovine model.
Materials and methods

Chemicals and materials
TCM was obtained as "Tobra-day" containing TMY sulfate equivalent to 500 mg of TCM in 5 mL water for injections (Pfizer, New York, NY, USA) and LMC was obtained as "Lincocin" containing LMC hydrochloride equivalent to 600 mg of LMC in 2 mL water for injection (Pfizer, New York, NY, USA). Vancomycin (VCM) was obtained as "Vancocin CP" containing chromatographically purified VCM equivalent to 500 mg lyophilized powder (Aspen, St Leonards, NSW, Australia).
The chemical structures for these compounds are shown in Figure 1 . Acetonitrile was of LCMS grade (Merck, Darmstadt, Germany), and formic acid (Fisher Scientific, Scoresby, VIC, Australia), ammonium acetate (Chem-Supply, Adelaide, SA, Australia) and trichloroacetic acid (TCA, Ajax Finechem, NSW, Australia) were of analytical grade. Milli-Q water from a Permutit system was used. Drug-free human plasma (containing lithium heparin as the anticoagulant) was obtained from Innovative Research (Novi, MI, USA) and drug-free urine was obtained from healthy volunteers. Ethics 
Chromatographic conditions and detection
An UHPLC (Shimadzu Nexera2)-integrated system consisting of dual pump, a degasser, column oven at 24 ± 2 °C and an autosampler with a sample compartment set to 5 °C was used. The stationary phase for TMC was a SeQuant zic-HILIC column, 2.1 × 20 mm, 5.0 μm analytical guard column, while the stationary phase for LMC was a SeQuant zic-HILIC column, 2.1 × 50 mm, 5.0 μm analytical column equipped with a SeQuant zic-HILIC column, 2.1 × 20 mm, 5.0 μm guard column. Mobile phase A was prepared to contain 2 mM ammonium acetate in 10% acetonitrile with 0.2% formic acid (v/v) and mobile phase B contained 2 mM ammonium acetate in 90% acetonitrile with 0.2% formic acid (v/v). An optimized gradient elution with constant flow rate of 0.4 mL/min was used. For the separation of TMC the gradient started at 80% of mobile phase B for the first 0.5 min and then decreased linearly to 10% of mobile phase B for 1.5 min. This condition was held for 1.0 min and increased linearly for 1 min, returning to 80% mobile phase B. This final condition was kept for 2 min to re-equilibrate the chromatography column. The total run time was 6.5 min. The gradient used for the separation of LMC started at 100% of mobile phase B for 0.5 min and then decreasing linearly to 40% of mobile phase B for 1.5 min. This condition was held for 1 min and then increased linearly for 1 min, returning to 100% of mobile phase B. This final condition was held for 2.5 min to re-equilibrate the chromatography column. The total run time was 6.5 min.
Identification and detection of analytes were performed using a triple quadrupole mass spectrometer (Shimadzu 8030+) equipped with an ESI turbo ion source operated in positive mode under the control of a software (v5.42 SP4; LabSolutions, Shimadzu, Japan). A 100 ms dwell time was used and the analytes, i.e. TMC, LMC and VCM (internal standard) were monitored using multiple reaction monitoring mode (Table 1 ). Nitrogen was used as the nebulizing gas. The interface nebulizing gas flow was set to 3 L/min, a de-solvation line temperature 250 °C, heat block temperature 400 °C and a drying gas flow of 10 L/min. The collision gas was argon. The analyte fragmentation voltage and collision energies are reported in Table 1 .
Preparation of standards and samples
Drug-free matrix preparation: To aid the quantification of microdialysis fluid, simulated drug-free microdialysis fluid was prepared by mixing of 10% ultrafiltered plasma in 90% compound sodium lactate solution. Drug-free ultrafiltered plasma was yielded by filtering drug-free plasma through pre-heated centrifree® ultrafiltration devices (Merck Millipore Ltd., Cork, Ireland), in pre-heated centrifuge buckets and then centrifuging at 37 °C for 5 min at 2400 g. For the quantification of urine and to match the dilution performed on the study samples, the drug-free urine was prepared as a dilution of 5% urine in water (v/v).
Preparation of calibration standards and quality controls:
Aqueous stock solutions of TMC and LMC were separately prepared to contain 1000 mg/L concentrations of each analyte. For quantification of TMC and LMC in plasma, the calibration stock was prepared in water (containing 5, 10 and 20 mg/L), simulated drug-free microdialysis fluid (5, 10 and 20 mg/L) and drug-free urine (20, 50 and 100 mg/L), respectively. All calibration stocks were stored at −80 °C. On the day of assay, calibration standards for plasma (eight calibration standard concentrations, i.e. 0.1, 0.2, 0.5, 1, 2, 5, 10 and 20 mg/L for TCM and nine calibration standard concentrations, i.e. 0.05, 0.1, 0.2, 0.5, 1, 2, 5, 10 and 20 mg/L for LMC), microdialysis (eight calibration standard concentrations 0.1, 0.2, 0.5, 1, 2, 5, 10 and 20 mg/L for both TCM and LMC) and urine samples (seven calibration standard concentrations 1, 2, 5, 10, 20, 50 and 100 mg/L for both TCM and LMC) were prepared by serial dilution with water, simulated drug free microdialysis fluid and drug free urine, respectively. Plasma calibration samples were prepared by mixing 100 μL of drug-free plasma with 100 μL of calibration standard solution.
Quality control samples were prepared using stock solutions of 1000 mg/L TMC and LMC and diluted with drug-free matrix (plasma, simulated drug-free microdialysis fluid or drug-free urine). Quality control samples were prepared at plasma concentrations of 0.3, 2 and 16 mg/L of TMC and 0.15, 2 and 16 mg/L of LMC, at microdialysis fluid concentrations of 0.3, 2 and 16 mg/L for both TMC and LMC, and at urine concentrations of 3, 20 and 160 mg/L for both TMC and LMC. Quality control samples were stored at −80 °C and processed alongside the study samples.
A stock solution of the internal standard, VCM was prepared in water at 100 mg/L for the analysis of plasma and microdialysis fluid, and at 1000 mg/L for the analysis of urine. All internal standard solutions were stored at −20 °C or below.
Sample preparation:
To match the dilution of the calibration standards, 100 μL of each plasma study sample or quality control sample was mixed with 100 μL of drug-free water. A 50 μL aliquot of the internal standard solution (100 mg/L of VCM) and 50 μL of 15% TCA were added. The mixture was then vortexed for 3 s and subsequently centrifuged (at 2000 g for 5 min). An aliquot of supernatant (100 μL) was transferred to an autosampler vial for chromatographic analysis. Injections of 2 μL and 0.2 μL were performed for the quantification of plasma samples for TMC and LMC, respectively.
For the analysis of microdialysis fluid, 10 μL of the microdialysis fluid study sample, quality control sample and calibration standards were spiked with 30 μL of internal standard (100 mg/L of VCM) in a microfuge tube. The sample was vortexed and a 30 μL aliquot of sample was transferred to an autosampler vial for analysis. Injections of 2 μL and 0.2 μL were performed for the quantification of microdialysis fluid samples for TMC and LMC, respectively. For urine analysis, the clinical samples were filtered and diluted with water (5%, v/v), then 50 μL of the urine study sample, quality control sample and calibration standards were diluted with 50 μL of internal standard (1000 mg/L of VCM) in a microfuge tube. The solution was vortexed, and transferred to autosampler vial. Injections of 0.5 μL and 0.1 μL were performed for the quantification of microdialysis fluid samples for TMC and LMC, respectively.
Data analysis
For both TMC and LMC, the concentration of each sample was obtained using the data from the calibration curve prepared from calibration standards within each batch. Data for TMC was analyzed using a quadratic regression with peak area ratio (analyte/internal standard area response) against concentration (x) with a 1/concentration 2 weighting, and for LMC quadratic with 1/concentration weighting was used as the mathematical basis for quantification.
Method validation
The method validation was performed in accordance with the U.S. Food and Drug Administration (USFDA) guidelines [24] . The validation for all matrices was assessed for linearity, matrix effects, selectivity, lower limit of quantification (LLOQ), stability and inter-day and intra-day precision and accuracy. Recovery of analytes (TMC and LMC) was measured only for plasma matrix, as no extraction was performed for the other matrices.
The limit of detection (LOD) was calculated using the lowest concentration of the calibration standards and determined based on achieving a signal to noise ratio of 3. The lower limit of quantification (LLOQ) is the lowest concentration that presents an intra-batch precision below 20%. The selectivity of the method was investigated to confirm there was no enhancement of suppression of signal used for the quantification of analytes in the presence of drug-free matrices. Method selectivity was performed by spiking drug-free matrix at the LLOQ concentrations for TMC and LMC in plasma (obtained from various sources and including different anticoagulants, n = 6), simulated drug-free microdialysis fluid (prepared using various sources of plasma and including different anticoagulants, (n = 6), and drugfree urine (collected from various sources, n = 6). The results were assessed for precision and accuracy (of nominal concentrations) meeting the criteria of ±15% for acceptance.
To understand the matrix effect on the signal profile of TMC and LMC, six drug-free matrix samples, for each matrix, were assayed at concentration of 1, 4 and 16 mg/L for TMC and LMC in plasma and microdialysis fluid, and 5, 16 and 80 mg/L for TMC and LMC in urine). The internal standard was added during the extraction. The matrix effect was evaluated by comparing the peak area of the analyte in matrix to the peak area of the analyte when prepared in water instead of matrix. The precision of the matrix factor (normalized against internal standard) was used to determine variability from the expected result. The recovery of TMC and LMC was calculated by comparing peak area ratio of analytes spiked into drug-free plasma and extracted using the protein precipitation procedure described in 2.3.3 to the post-extraction drug-free plasma supernatant spiked at concentrations of 1, 4 and 16 mg/L, ensuring the dilution volumes were matched for both the pre-extracted and post-extracted samples.
To investigate linearity, the calibration curve was prepared using concentration ranges suitable for a pharmacokinetic research study, in all matrices. Intra-day precision and accuracy were determined by performing at least five replicates of each quality control sample at concentrations of 0.3, 2 and 16 mg/L for TMC and LMC in plasma and microdialysis fluid and 3, 16 and 80 mg/L for TMC and LMC in urine, extracted alongside a set of matrix-matched calibration standards. The same procedure was repeated on at least three different days including fresh calibration and triplicate quality control samples to determine inter-day precision and accuracy (n = 9 for each concentration of quality control). Precision was calculated as relative standard deviation and accuracy as percent deviation from the nominal concentration.
The stability of TMC and LMC was analyzed in frozen storage (at −80 °C), at room temperature (for 4 h at 24 °C), and across three freezethaw cycles (from −80 °C to room temperature). This was performed using three replicates of quality control samples at concentrations of 0.3, 2 and 16 mg/L for TMC and LMC in plasma and microdialysis fluid and 3, 16 and 80 mg/L for TMC and LMC in urine. Stability was calculated for TMC and LMC by comparing the experimental values to nominal concentrations. Stability of stock solutions prepared in water and stored at −80 °C were assessed by comparing the analyte area obtained from stored solutions to that obtained for freshly prepared solutions, with the results deemed acceptable if the analyte area (n = 6 injections) from the stored solution was within 5% of the area of the freshly prepared solution. The stability of processed samples stored on the auto-sampler at 4 °C was tested by comparing stored quality control samples concentrations to the concentrations of the samples obtained prior to storage. The stored samples were reinjected alongside the original calibration curve (which was also stored on the autosampler at 4 °C), with the results of the stored calibration curve being used to calculate the concentrations of the stored samples. The storage conditions were deemed acceptable if the concentrations of the stored samples were within 5% of the sample concentrations obtained prior to storage for all of the paired samples tested.
Pharmacokinetic application
These methods were applied to the analysis of microdialysis fluid, plasma and urine samples collected for a pharmacokinetic research study in three healthy sheep receiving intravenous or nebulized TMC or LMC. Ethics approval was obtained from the Queensland University of Technology (Chermside, Australia) animal Ethics Committee (approval No. 1100000052). Sheep were anesthetized, mechanically ventilated and administered nebulized TMC (400 mg, Tobra-day®, Phebra) and LMC (600 mg, Lincocin®, Pfizer). Microdialysis probes (CMA 63; CMA Microdialysis AB, Stockholm, Sweden) were inserted, one each in the upper and lower lung lobes of the right lung. An intravascular microdialysis catheter (CMA 64; CMA Microdialysis AB, Stockholm, Sweden) was inserted in the left jugular vein through a percutaneously inserted 18G cannula (B. Braun Australia Pty Ltd., Bella Vista, Australia). The microdialysis catheters were perfused using CMA 107 pumps (CMA Microdialysis AB, Stockholm, Sweden) at 1 μL/min. Samples were collected every 20 min for 8 h in a microvial (CMA, Microdialyisis AB) and stored at −80 °C [25] . A blood sample (2 mL) was collected prior to dosing and repeated at 1 h and 6 h after the completion of drug administration from a separate intravascular catheter to which the drug was administered. Blood samples were collected using heparinized vacuum tubes (Greiner Bio-One, Vacuette® lithium heparin) and centrifuged at 1400 g for 10 min to obtain plasma samples. The plasma samples were subsequently transferred into 2 mL polypropylene tubes and stored at −80 °C. The urine sample was collected as a pooled sample of urine collected from 0 to 8 h (2-h intervals), post administration of the TMC and LMC dose. An aliquot of urine was transferred into a urine specimen vial and stored at −80 °C.
Results and discussion
Chromatography and detection
Two HILIC methods for the quantification of TMC and LMC in plasma, microdialysis fluid and urine were successfully developed (Figure 2 ). The optimal chromatographic retention conditions for the analytes necessitated the use of two columns and different mobile phase gradient profiles. For TMC, sufficient retention was achieved using a 20 mm analytical guard column (retention time of 1.7 min, 3.9 min. and 2.9 min. in plasma, microdialysis fluid and urine, respectively), while for LMC optimal retention required the use of a 50 mm analytical column (equipped with an analytical guard column) (retention time of 1.4 min, 2.1 min. and 0.9 min. in plasma, microdialysis fluid and urine, respectively). The results of investigating the retention of TCM on the 50 mm analytical column, as used for LMC, found unsuitably long retention times (>10 min) and broad, tailing peaks, even with adjustments to the mobile phase gradient profiles. Conversely, LMC was poorly retained on the 20 mm analytical guard column. The internal standard VCM eluted at 0.5 min (in plasma), 1.5 min (microdialysis fluid) and 2.0 min (urine) with the TMC assay method. With the LMC assay method, VCM retention time was 1.7 min, 2.6 min and 2.4 min in plasma, microdialysis fluid and urine, respectively. The extraction volume from the analysis provided a sufficient sample to perform the duplicate injections required for this chromatographic analysis, with overnight runs performed using automated column switching. These methods employ positive selected reaction monitoring (SRM) for TMC, LMC and VCM as an internal standard ( Table 1) . Protonated molecular ions and corresponding product ions of TMC, LMC and VCM were manually selected initially (Figure 1 ). Software directed infusions were then performed to optimize voltages and to identify any alternative fragmentation pattern available that may lead to the highest response. The product ion of TMC at the m/z ratio of 163.20, results from the cleavage of the glycosidic bonds and the subsequent loss of the amino-sugar rings [13] . For LMC, following the loss of the 3-propyl-N-methylpyrrolidine ion, a product ion at m/z ratio of 126.3 was observed [26] . An abundant precursor ion at m/z ratio of 725.6 corresponded to a double-charged [M + 2H] 2+ ion for the internal standard, VCM. The product ion of VCM at the m/z ratio of 144.1 results from separation of the two parts of the glycoside group [27] .
Validation
During validation and analysis of study samples, within the batch run order two samples, one containing a drugfree matrix with an internal standard and one containing a drug-free matrix, were injected to inspect for any potential carryover between injections. No carryover effect was observed for TMC or LMC in all of the matrices tested.
Due to a positive parabolic (non-linear) mass spectrometer response observed with increasing concentrations of TMC and LMC across a wide calibration range a linear regression was unsuitable. A quadratic regression with a 1/concentration 2 weighting for TMC and 1/concentration weighting for LMC provided a reliable adequate calibration equation within the concentration range. The calibration range, mean correlation coefficient (r 2 ) and the percentage of maximum deviation (inaccuracy) of the standards of calibration curves for all matrices are presented in Table 2 .
The LOD for TMC in plasma, microdialysis fluid and urine was <0.01, 0.02 and 0.05 mg/L, respectively, and for LMC was 0.003, 0.02 and 0.02 mg/L, respectively. The intra-and inter-batch precision and accuracy of the plasma, microdialysis fluid and urine are reported for TMC and LMC (Tables 3 and 4 ). All precision and accuracy results met the acceptance criteria. The selectivity for quantification of TMC and LMC was tested at the lower limit of quantification in plasma (drug-free plasma contained lithium heparin, sodium oxalate or ethylenediaminetetraacetic acid), microdialysis fluid and urine (n = 6 for each matrix). For TMC in plasma, microdialysis fluid and urine the selectivity results were 0.11, 0.10 and 0.90 mg/L with precision of 8.1%, 8.0% and 7.7%, and accuracy of 11.0%, 2.6% and −9.7%, respectively. The selectivity results for the quantification of LMC in plasma, microdialysis fluid and urine were 0.05, 0.11 and 0.89 mg/L with precision of 7.2%, 10.0% and 8.1%, and accuracy of 8.6%, 6.2% and −10.8%, respectively. These results met the preestablished acceptance criteria.
Testing of the matrix effect is reported in Table 5 , with results showing variability within an acceptable range for the response of TMC or LMC in plasma, microdialysis fluid and urine. Signal suppression was observed for VCM in plasma matrix for both methods. As the matrix suppression observed is for the internal standard and this result will be consistent for all samples, as the internal standard is added at the same volume and concentration to all samples, calibration standards and quality control samples. The matrix suppression observed for VCM was 0.53 ± 0.07 (n = 18 samples across three concentrations) with a precision of 13.2% for the analysis of TMC and 0.59 ± 0.06 (n = 18 samples across three concentrations) with a precision of 10.2%) for the analysis of LMC. Cheng et al. studied and reported better recovery of aminoglycosides after pre-treatment with TCA with comparison to acetonitrile from plasma samples [26] . The mean recovery from the processing of plasma was 91.2 ± 7.3% for TMC and 93.2 ± 5.2% for LMC (Table 5 ). Recovery testing was not performed for microdialysis fluid and urine as the sample preparations for these matrices involved dilution followed by direct injection only. The results of the stability studies are shown in Tables 6 and 7 for TMC and LMC, respectively. Both analytes were stable in all matrices when tested at room temperature for 4 h and when undergoing three freeze-thaw cycles. Following more than a year of storage quality control samples prepared in plasma, microdialysis fluid and urine demonstrated acceptable stability, with a maximum concentration deviation of 1.8% and 1.3% for TMC and LMC, respectively. Testing of aqueous stock solutions of TMC and LMC for 4 months at −80 °C showed acceptable deviations of −1.1% and −2.3%, respectively. Testing of the suitability of storage of processed samples on the autosampler at 4 °C was performed by comparing the deviation between paired samples (n = 6) from prior to storage and then when reinjected after storage. After 48 h of storage on the autosampler the mean deviation for TMC in plasma, microdialysis fluid and urine was found −2.3%, 4.6% and 3.1%, respectively. For LMC in plasma, microdialysis fluid and urine a mean deviation of −3.7%, 2.8% and 2.7% was found after 48 h of storage at 4 °C, respectively.
A limitation of our validation was that we were unable to obtain drug-free sheep plasma to perform the validation and have used drug-free human plasma as a surrogate.
Pharmacokinetic application
This method was successfully applied to the analysis of samples in a study describing lung pharmacokinetics for nebulized formulations of TMC and LMC (AEC approval SOM/268/16/RBWH) [28] . The calibration range selected for the assay methods of TMC and LMC in plasma, microdialysis fluid and urine was based on the results of previous published pharmacokinetic and clinical studies. The concentration range of TMC was reported approximately 2.0-22.3 mg/L in osteomyelitis drainage tissue fluid [5] , 0.2-15.4 mg/L in serum [6] , 0.4-0.7 mg/L in bone tissue [7] and 0.1-10 mg/L in healthy volunteer plasma [21] , and LMC concentration range was approximately 5.6-21.3 mg/L in cat serum [29] and 6-20 mg/L in healthy volunteer plasma [30] . Following a 100 mg/mL nebulized dose of TMC and LMC, the plasma concentrations of TMC and LMC ranged from 3.96 to 8.26 mg/L and 0.24 to 0.27 mg/L, respectively. A concentration-time profile of microdialysis fluid obtained in the upper and lower lobe of the right lung from a healthy Merino sheep post-nebulized dose of TMC and LMC is presented in Figure 3A and B, respectively. The peak microdialysis fluid concentration (C max ) was 33.1 mg/L and 26.2 mg/L for TMC and LMC, respectively. The lowest concentration (C min ) measured in microdialysis fluid was 1.05 mg/L and 1.16 mg/L for TMC and LMC, respectively. The concentrations in urine for TMC and LMC ranged from 473.19 to 888.13 mg/L and 229.80 to 511.56 mg/L, respectively.
Conclusions
Simple and robust HILIC-MS methods were established for the quantification of TMC and LMC concentrations in plasma, microdialysis fluid and urine. The proposed methods use an inexpensive sample preparation and a small sample volume, making it suitable for small animal research, as well as research in humans. The assay performance was accurate and precise, with adequate sensitivity. This methodology has been successfully applied to a pilot pharmacokinetic research study performed in sheep model. 
